ReviewCurrent treatment options in oncology2023
An Update on Appendiceal Neuroendocrine Tumors.
Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 11 citations in OpenAlex.
- Gender, Sex and Other Factors in the Development of Neuroendocrine Neoplasms.Current oncology reports · 2026Review
- Article
- Article
- Surgical outcomes of laparoscopic and open appendectomy in pregnant patients: A single-center retrospective cohort study.Turkish journal of surgery · 2026Article
- Unusual histopathologic findings of appendectomy specimens: A retrospective study of cases at Jordan University Hospital over the last decade (2015-2024).Saudi medical journal · 2025Article
- Analysis of clinicopathological characteristics and prognosis of appendiceal neuroendocrine tumors: a retrospective cohort study based on the SEER database.Translational cancer research · 2025Article
- Survival outcomes of local versus radical resection for appendiceal neuroendocrine tumors: a population-based study.Translational cancer research · 2025Article
- A case of well-differentiated neuroendocrine tumor of the appendix in a 14-year-old male adolescent clinically presented with features of acute appendicitis: A case report and literature review.International journal of surgery case reports · 2025Article
- Appendiceal neuroendocrine tumors: a case series and literature review.Journal of surgical case reports · 2025Article
- A case of appendiceal neuroendocrine tumor with metastatic spread in a young patient.SAGE open medical case reports · 2025Article
- Factors Affecting Survival Outcomes in Neuroendocrine Tumor of the Appendix over the Past Two Decades.Diseases (Basel, Switzerland) · 2024Article
- Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment.Frontiers in endocrinology · 2024Review
- Article
- Appendiceal Neuroendocrine Tumor: Clinicopathologic Characteristics of Six Cases and Review of the Literature.In vivo (Athens, Greece)Review
- Incidentally discovered, intentionally managed: a narrative review of the last decade's updates on the management of neuroendocrine tumor of the appendix.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mainstay of appendiceal neuroendocrine neoplasm (aNEN) treatment is surgery, based on simple appendectomy or right-sided hemicolectomy with lymphadenectomy (RHC). The majority of aNENs are adequately treated with appendectomy, but current guidelines have poor accuracy in terms of selecting patients requiring RHC, especially in aNENs 1-2 cm in size. Simple appendectomy is curative for appendiceal NETs (G1-G2) < 1 cm (if the resection status is R0), whereas RHC with lymph node dissection is recommended in tumors ≥ 2 cm in diameter, based on the high risk of nodal metastases in these cases. The clinical management of aNENs 1-2 cm in size is more controversial because lymph node or distant metastases are uncommon but possible. In our opinion, patients with tumor size > 15 mm or with grading G2 (according to WHO 2010) and/or lympho-vascular invasion should be referred for radicalization with RHC. However, decision-making in these cases should include discussion within a multidisciplinary tumor board at referral centers with the aim of offering each patient a tailored treatment, also considering that relatively young patients with long-life expectancy represent the majority of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.